924 related articles for article (PubMed ID: 29179873)
1. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873
[TBL] [Abstract][Full Text] [Related]
2. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
4. Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries.
Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Griffiths UK; Feletto M; Burchett HED; LaMontagne DS; Watson-Jones D
PLoS One; 2017; 12(6):e0177773. PubMed ID: 28575074
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries.
LaMontagne DS; Barge S; Le NT; Mugisha E; Penny ME; Gandhi S; Janmohamed A; Kumakech E; Mosqueira NR; Nguyen NQ; Paul P; Tang Y; Minh TH; Uttekar BP; Jumaan AO
Bull World Health Organ; 2011 Nov; 89(11):821-830B. PubMed ID: 22084528
[TBL] [Abstract][Full Text] [Related]
6. Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program, Cambodia - 2017.
Garon J; Wuddhika IV; Sreenivasan N; Wannemuehler K; Vutthikol Y; Chhorvann C; Loharikar A
Vaccine; 2019 Feb; 37(9):1202-1208. PubMed ID: 30686637
[TBL] [Abstract][Full Text] [Related]
7. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
[TBL] [Abstract][Full Text] [Related]
8. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis.
Bruni L; Diaz M; Barrionuevo-Rosas L; Herrero R; Bray F; Bosch FX; de Sanjosé S; Castellsagué X
Lancet Glob Health; 2016 Jul; 4(7):e453-63. PubMed ID: 27340003
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
Owsianka B; Gańczak M
Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
[TBL] [Abstract][Full Text] [Related]
10. Social mobilisation, consent and acceptability: a review of human papillomavirus vaccination procedures in low and middle-income countries.
Kabakama S; Gallagher KE; Howard N; Mounier-Jack S; Burchett HE; Griffiths UK; Feletto M; LaMontagne DS; Watson-Jones D
BMC Public Health; 2016 Aug; 16(1):834. PubMed ID: 27543037
[TBL] [Abstract][Full Text] [Related]
11. Improving skills and institutional capacity to strengthen adolescent immunisation programmes and health systems in African countries through HPV vaccine introduction.
Dochez C; Burnett RJ; Mbassi SM; Were F; Musyoki A; Trovoada D; Mphahlele MJ
Papillomavirus Res; 2017 Dec; 4():66-71. PubMed ID: 29179872
[TBL] [Abstract][Full Text] [Related]
12. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
15. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013.
Ladner J; Besson MH; Rodrigues M; Audureau E; Saba J
BMC Public Health; 2014 Jun; 14():670. PubMed ID: 24981818
[TBL] [Abstract][Full Text] [Related]
16. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
17. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
[TBL] [Abstract][Full Text] [Related]
18. Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project - Botswana, 2013.
Raesima MM; Forhan SE; Voetsch AC; Hewitt S; Hariri S; Wang SA; Pelletier AR; Letebele M; Pheto T; Ramogola-Masire D; El-Halabi S
MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(40):1147-9. PubMed ID: 26468997
[TBL] [Abstract][Full Text] [Related]
19. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives.
Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM
S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566
[TBL] [Abstract][Full Text] [Related]
20. Human papilloma virus vaccine for low and middle income countries: A step too soon?
Jindal HA; Kaur A; Murugan S
Hum Vaccin Immunother; 2017 Nov; 13(11):2723-2725. PubMed ID: 28846491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
